Clicky

Using its proprietary platforms Retrocyte Display™ and SECANT®, the Company is discovering and developing novel antibodies to target GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed checkpoints in partnered and internal programs. placebo in patients over 70 years old. The high efficacy seen is in line with the efficacy shown in the first pivotal Phase 3 study in adults aged 50 years and over presented earlier this year. Using its proprietary platforms Retrocyte Display™ and SECANT®, the Company is discovering and developing novel antibodies to target GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1, CEACAM1 and other undisclosed checkpoints in partnered and internal programs. This efficacy was maintained with an 88% reduction in the risk of shingles (95% confidence interval: 73-95%) in the fourth year after vaccination. The Underdog from the Underground takes on the curator of “The List of Jericho,” with Old Glory on the line. The candidate vaccine is one of the more than 40 assets profiled to investors at GSK’s R&D event in November 2015 and belongs to the company’s vaccines portfolio – one of six core areas of scientific research and development alongside oncology, immuno-inflammation, and infectious, respiratory and rare diseases.


The risk of developing shingles increases with age and altered immune system status. The candidate vaccine is one of the more than 40 assets profiled to investors at GSK’s R&D event in November 2015 and belongs to the company’s vaccines portfolio – one of six core areas of scientific research and development alongside oncology, immuno-inflammation, and infectious, respiratory and rare diseases. 14, 2016 — An experimental vaccine against shingles may offer lasting protection for most older adults who receive it, a new clinical trial found. GSK’s candidate shingles vaccine is a non-live vaccine and combines gE, a protein found on the virus that causes shingles with an adjuvant system, AS01B ii, which enhances the immunological response to gE. GSK Vaccines R&D senior vice president and head Dr Emmanuel Hanon said: “Shingles is a common but serious condition that results from the reactivation of the virus that causes chicken pox and can cause lasting pain and other complications. The company added that the trial’s independent Data Monitoring Committee, in its ongoing review of the safety information up to 31 May, raised no concerns regarding the continuation of the study. But importantly, the researchers believe this vaccine is a valuable option for people unable to take a live vaccine.

It typically presents itself as a painful, itchy rash that develops on one side of the body, as a result of reactivation of latent chickenpox virus (varicella zoster virus, VZV). To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today. The authors noted that efficacy of the vaccine was 90 percent among study participants whose ages ranged from 70 years to 79 years, and 89 percent in those aged 80 years and older. Vaccine efficacy for herpes zoster (HZ) burden of illness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were assessed for the STPS population, for the combined SPS and STPS populations, and for each year through year 7 after vaccination. GSK today also announced that, as per the stepwise trial design of its losmapimod Phase III study, LATITUDE-TIMI 60, an interim review of data from part A of the study (an initial cohort of 3,503 patients) did not indicate efficacy against the primary endpoint and did not support investment in the larger part B of the study as currently designed. This efficacy was maintained with an 88% reduction in the risk of shingles (95% confidence interval: 73-95%) in the fourth year after vaccination. In a recent editorial April 28, 2015 in the New England Journal of Medicine the overall vaccine efficacy against herpes zoster was 97.2% and the Vaccine efficacy was between 96.6% and 97.9% for all age groups.

The difference between Zostavax, which is recommended for adults older than 60, and the varicella vaccine (Varivax®), which is recommended for all young children, is that Zostavax contains roughly 14 times more Oka strain of varicella vaccine than Varivax. GSK’s candidate shingles vaccine is a non-live vaccine and combines gE, a protein found on the virus that causes shingles with an adjuvant system, AS01Bii, which enhances the immunological response to gE. Based on these and the previously reported ZOE-50 data, GSK says it expects to start submitting regulatory applications for the candidate vaccine for the prevention of shingles in people 50 years and above later this year. This gives HZ/su an advantage over Zostavax, the efficacy of which declines in older people. Doses 2 through 4 will be administered 30, 60 and 90 days post-HCT. The shingles vaccine is recommended for adults 60 and older. In all models, the interaction between vaccine-group and chronological-age was statistically significant indicating that vaccine efficacy decreases with the expected effects of advancing age but the interaction between vaccine-group and time-since-vaccination was not statistically significant indicating that much of the reduction in vaccine efficacy over time-since-vaccination can be explained by increasing age.